Immatics Announces Pricing of $150 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...
Immatics Announces Proposed $150 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...
Immatics: A Promising TCR Pipeline
Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...
FierceBiotech6d
Immatics' cell therapy leapfrogs into phase 3 on strength of early-stage survival data
Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...
Buy Rating Affirmed for Immatics Amidst Promising Clinical Trials and Strategic Positioning in TCR Therapeutics
Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX – Research Report) on October 11 and set a price target ...
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering ...
The Pharma Letter5d
Immunotherapy firm Immatics prices $150 million public offering
German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...
Immatics Reports Updated Phase 1b Data Of IMA203 In Melanoma Patients
In the Phase 1b dose expansion part of the study, heavily pretreated patients with metastatic melanoma were treated with IMA203. Data from the study showed a significant positive shift in median ...
Immatics Shares Drop After Launching $150M Public Offering
Immatics shares were down 10% to $9.95 after the company began a proposed $150 million underwritten public offering of its ordinary shares.